JNP Medi (CEO Jeong Gwon-ho), a consulting firm for the development of new drugs and innovative medical devices based on an AI platform, announced on the 14th that it has signed a memorandum of understanding (MOU) with Korea University Technology Holdings Co., Ltd. (CEO Woo Sang-hyun) and established a strategic cooperation system to increase the clinical entry and commercialization success rate of technology-based biohealth startups.
Through this agreement, J&P Medi will operate a special CRO support program for startups discovered and recommended by Korea University Technology Holdings. In addition to providing preferential CRO services, J&P Medi will assign a dedicated core A-team to oversee the entire process, from strategy development to IND preparation and clinical trials, to enhance the quality of clinical execution. Furthermore, J&P Medi will provide full-cycle consulting services, including preclinical and clinical trial design, regulatory strategy, and product approval roadmap development, systematically supporting the clinical success potential of companies in the Technology Holdings portfolio.
The two organizations will establish a permanent collaboration channel to continuously introduce companies recommended by the technology holding company to J&P Medi. J&P Medi will share the experience and data accumulated during clinical trials to enhance the joint pipeline. Furthermore, J&P Medi is exploring participation as an LP (Limited Partner) in the technology holding company's fund, strengthening their long-term partnership in both clinical trials and investment.
Subsidiary JNP Medi Partners will provide investment and growth support through a collaborative structure. The two organizations plan to streamline the investment review process by sharing information on early-stage startups and conducting joint technology reviews, company assessments, and valuation discussions. They will also pursue joint fundraising focused on biohealth technology commercialization and dental specialization, as well as acceleration and business development (BD) programs.
“This agreement is significant in that it lowers the structural barriers that startups face during the clinical phase and establishes an execution-oriented collaboration model that naturally leads to commercialization and investment,” said Jeong Gwon-ho, CEO of JNP Medi. “We will enhance the global competitiveness of our portfolio companies through a support system that combines clinical expertise and investment linkages.”
- See more related articles
You must be logged in to post a comment.